Myelodysplastic Syndrome
📧 Sign up to get email alerts when something new happens for Myelodysplastic Syndrome.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial) [Phase 2]
A phase 2 trial is evaluating adding the IDH2 inhibitor enasidenib to cedazuridine-decitabine therapy for higher-risk myelodysplastic syndro…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome [Phase 1, Phase 2]
A phase 1/2 clinical trial is evaluating the combination of CPX-351 (liposomal cytarabine and daunorubicin) with Quizartinib for acute myelo…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations [Phase 2]
A Phase 2 clinical trial is investigating allogeneic hematopoietic stem cell transplantation for patients with GATA2 mutations, currently in…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) [Phase 2]
This is a Phase 2 screening trial (MYELOMATCH) sponsored by the National Cancer Institute to assign people with myeloid cancers to a treatme…
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: Evaluation of Antibiotic Prophylaxis in Myelodysplastic Syndromes and Acute Myeloid Leukemia (MYELO-CAN:ABX) [Phase 2]
This Phase 2 trial from the University of Manitoba is evaluating antibiotic prophylaxis in patients with myelodysplastic syndrome and acute …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-21Clinical Trial Update: Biology Studies of Hematologic Cancers
The document reports an NCI-sponsored biology-focused clinical trial update in hematologic cancers, with enrollment by invitation for condit…
-
CLINICAL_TRIALS research · 2026-04-21Clinical Trial Update: Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO) [Phase 1, Phase 2]
A clinical trial update on active myeloid-target compound combinations for myelodysplastic syndromes with myeloproliferative neoplasm overla…
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy [Phase 1]
This clinical trial aims to determine the highest tolerated dose of imetelstat when given with fludarabine and cytarabine in children with r…
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT [Phase 1]
Stanford is conducting a Phase 1 study evaluating cessation of tacrolimus immunosuppression after allogeneic hematopoietic cell transplantat…
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating the combination of azacitidine and quizartinib for patients with chronic myelomonocytic leukemia, myel…
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm [Phase 1, Phase 2]
This update describes a Phase 1/2 clinical trial evaluating a triplet regimen of azacitidine, venetoclax, and gilteritinib in patients with …
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations [Phase 2]
This entry outlines a Phase 2 clinical trial testing olutasidenib in combination with a co-targeted therapy for relapsed or refractory IDH1-…
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: Venetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome [Phase 2]
Phase 2 trial update evaluating venetoclax with sequential busulfan, cladribine, and fludarabine phosphate as conditioning before donor stem…
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: Romiplostim Versus rhTPO for Platelet Engraftment After Transplant in MDS and AA [Phase 2]
A Phase 2 clinical trial compares romiplostim to recombinant human thrombopoietin (rhTPO) for platelet engraftment after transplantation in …
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT [Phase 1, Phase 2]
A Phase 1/2 clinical trial is evaluating CD45RA-depleted stem cell addback to prevent viral or fungal infections following TCRab/CD19-deplet…
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome [Phase 2]
Phase 2 clinical trial evaluating a combination of methylprednisolone, horse anti-thymocyte globulin, cyclosporine, and growth factors (filg…
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia [Phase 1]
Phase 1 trial of Vyxeos (CPX-351) is investigating treatment of relapsed or refractory high-risk myelodysplastic syndrome and chronic myelom…
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: Study Investigating Patient-Reported Outcomes in Lower-risk MDS Patients
The study evaluating patient-reported outcomes in lower-risk myelodysplastic syndrome patients is currently active but not recruiting. Spons…
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome [Phase 1, Phase 2]
A Phase 1/Phase 2 clinical trial evaluating ONC201 for relapsed or refractory acute lymphoblastic leukemia, relapsed or refractory acute mye…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm [Phase 2]
Clinical trial update of a Phase 2 study evaluating venetoclax in combination with ASTX727 (oral decitabine/cedazuridine) for chronic myelom…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma [Phase 1]
A Phase 1 clinical trial evaluating the VSV-hIFNβ-NIS vaccine with or without cyclophosphamide and in combination with ipilimumab, nivolumab…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia [Phase 2]
Phase II open-label trial evaluating subcutaneous canakinumab (anti-IL-1β) for patients with low- to intermediate-1-risk myelodysplastic syn…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy) [Phase 2]
Clinical trial update outlining plans to study IDH1 inhibitor olutasidenib in combination with ASTX727 and venetoclax for acute myeloid leuk…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts [Phase 1]
Phase 1 clinical trial evaluating TAK-243 for relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes with increased bla…
-
CLINICAL_TRIALS research · 2026-04-09Clinical Trial Update: A Study Comparing Haploidentical Hematopoietic Stem Cell Transplantations (HSCTs) From Young Non-first-degree and Older First-degree Donors in Hematological Malignancies [Phase 3]
A Phase 3 clinical trial comparing haploidentical hematopoietic stem cell transplantation from young non-first-degree donors versus older fi…